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NanocompositesAbstract The aim of the present study is to examine the feasibility of Cassava starch acetate
(CSA)–polyethylene glycol (PEG)–gelatin (G) nanocomposites as controlled drug delivery systems.
It is one of the novel drug vehicles which can be used for the controlled release of an anticancer
drug. Simple nano precipitation method was used to prepare the carriers CSA–PEG–G nanocom-
posites and they were used for entrapping cisplatin (CDDP). Through FT-IR spectroscopy, the
linking among various components of the system was proved and with the help of scanning electron
microscope and transmission electron microscopy (TEM), the surface morphology was investigated.
The particle sizes of the CSA–CDDP, CSA–CDDP–PEG and CSA–CDDP–PEG–G polymer com-
posites were between 140 and 350 nm, as determined by a Zetasizer. Drug encapsulation efficiency,
drug loading capacity and in vitro release of CDDP were evaluated respectively. The findings
revealed that the cross linked CSA–PEG–G nanocomposites can be a potential polymeric carrier
for controlled delivery of CDDP.
 2015 University of Bahrain. Publishing services by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Starch, a biodegradable polymer is a promising carrier for
drug delivery. It has been used in various fields like biomedical,
agriculture and food etc. However, native starch cannot fit into
some parental controlled drug delivery systems, as many drugs
are released quickly from such unmodified starch-based sys-
tems (Michailova et al., 2001); due to considerable swelling
and quick enzymatic degradation of native starch in biological
systems.One of the efficacious methods, applied in this study to
improve the properties of starch, is the chemical modification
of starch which includes esterification. Over the past two dec-
ades extensive studies have been conducted on starch ester
called as acetylated starch (Wang and Wang, 2002). Chemi-
cally transformed starch acetates are less hydrophilic than
most of the other modified starches, due to the hydrophobic
nature of the acetoxy substituent (OCOCH3). In the drug
delivery applications, starch acetate has been extensively used
(Korhonen et al., 2004; Nutan et al., 2005, 2007; Pajander
et al., 2008; Pohja et al., 2004; Pu et al., 2011; Tuovinen
et al., 2004a,b; van Veen et al., 2005; Xu et al., 2009) and tissue
engineered scaffold has also been investigated (Guan and
Hanna, 2004; Reddy and Yang, 2009).
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important role. One of the most common anticancer agents
is Cisplatin (CDDP), the first generation of platinum based
chemotherapy drug. It is used in the treatment of solid tumors
including gastrointestinal, head and neck, genitourinary and
lung tumors (Kelland, 2007; Boulikas and Vougiouka, 2003).
The clinical application of cisplatin for cancer chemother-
apy is still in limited use because of its nonspecific bio-
distribution and severe side effects. In an attempt to overcome
this shortcoming, various studies have been conducted by
many groups. They are magnetically mediated controlled
delivery systems (Likhitkar and Bajpai, 2012), click chemistry
(Huynh et al., 2011), SiO2/polymer for the controlled release of
cisplatin (Czarnobaj and Lukasiak, 2007), platinum-tethered
gold nanoparticle (Brown et al., 2010). Chemotherapy with cis-
platin is connected with some serious side effects, such as:
vomiting, nephrotoxicity, ototoxicity, neuropathy, anemia
and nausea (Uchino et al., 2005). Owing to these side effects
other methods of administering cisplatin are required. In the
present study, CSA/PEG/G has been chosen as the raw mate-
rial to prepare the drug carrier.
Thekeyobjectiveof the current study is toencapsulate the anti-
cancer drug cisplatin (CDDP) into Cassava starch acetate/poly-
ethylene glycol/gelatin (CSA/PEG/G) nanocomposites through
the interaction between cisplatin (CDDP) and CSA/PEG/G
nanocomposites. Gelatin is a naturally occurring biodegradable
macromolecule with well-documented biocompatible properties
over other syntheticpolymers thatmake it an appropriatematerial
to be used as a nanoparticulate carrier (Lai et al., 2006). To
develop the microspheres, nanoparticles and polymers, Polyethy-
lene glycol (PEG), a suitable graft-forming polymer, has been
extensively employed in pharmaceutical and biomedical fields
(Jeong et al., 2008). The viability of CDDP-loaded polymeric
nanocomposites as a drug delivery system was verified by
evaluating its in vitro studies and instrumental characteristics.
2. Materials and methods
2.1. Materials
Native Cassava starch powder was obtained from Sago Serve
Industries (Salem, India). Acetic acid (P99%) and acetic
anhydride (P98%) were of analytical grade procured from
Sigma–Aldrich (St. Louis, USA). PEG 10000, gelatin Type-
B, phosphate-buffered saline (PBS) were prepared in deionized
water using NaCl (0.14 M), KCl (2.68  103 M), Na2HPO4
(0.01 M), KH2PO4 (1.76  103 M). Sodium hydroxide
(NaOH) and absolute ethanol were purchased from Merck
(Mumbai, India Ltd). Cisplatin was obtained from Dabur
Pharma Ltd. (New Delhi, India). All chemicals were used with-
out additional purification.
2.2. Preparation of cassava starch acetate
Native cassava starch was permitted to react with acetic anhy-
dride (1:4 ratio) with pyridine as a catalyst as previously
described (Singh and Nath, 2012) with few modifications.
Before acetylation, cassava starch was dried in an oven for
20 h at 45–60 C. Dried starch (25 g) was mixed with acetic
anhydride (100 g) through the medium of pyridine (200 g).The reaction was carried out at 120 C for a period of 3 h.
The final product was precipitated with ethanol, filtered and
dried in vacuum oven. Lastly, the modified starch was milled
and sifted in a sieve (#50 mesh) to obtain a homogeneous par-
ticle size and stored in desiccators until further study.
2.3. Preparation of CSA–CDDP nanorods
The CSA nanorods were prepared by a simple nanoprecipita-
tion technique as reported by Chin et al., 2011 with slight mod-
ification. CSA (10 mg) was dissolved in 8:10 wt% of NaOH/
urea (NU) solution mixtures; this solution mixture was used
as a solvent system for the dissolution of acetylated cassava
starch. Cisplatin was dissolved in CSA solution and prepared
at various concentrations i.e., 10%, 20%, 30%, 40% and
50%, using 4, 8, 12, 16 and 20 mg of drug, respectively. An ali-
quot of CSA solution (10 mg/mL) containing the various con-
centrations of the drugs was added drop-wise into a 10 ml of
absolute ethanol solution, which was constantly stirred using
a magnetic stirrer at a constant stirring rate (1500 rpm). The
CSA nanorods were made immediately. This dispersion of
nanorods was vacuum evaporated to remove the organic sol-
vent fully. Finally the resultant mixture was centrifuged at
13,000 rpm and the supernatant was removed to obtain the
CSA-cisplatin nanorods and freeze-dried at 40 C for 20 h.
2.4. Preparation of the CSA–CDDP–PEG and CSA–CDDP–
PEG–G nanocomposites
The various percentage of encapsulated CSA–CDDP in the
PEG and G solution were prepared by a method described
in our previous report (Rajan et al., 2013) as follows. First,
10% of PEG solution was prepared in water. Then, the solu-
tion was gradually added to a correct portion of the CSA–
CDDP nanorods under constant magnetic stirring at room
temperature for 1 h. The resulting encapsulated nanocompos-
ites (CSA–CDDP–PEG) were collected by centrifugation at
1500 rpm and freeze-dried at 30 C for 20 h. Later gelatin
(20 mg) was dissolved in water in a similar manner and grad-
ually added to CSA–CDDP–PEG nanocomposites under con-
stant magnetic stirring at room temperature for 1 h. Finally the
resulting encapsulated nanocomposites (CSA–CDDP–PEG–
G) were collected by centrifugation at 1500 rpm and freeze-
dried at 30 C for 20 h.
2.5. Particle size analysis
Drug loaded polymeric nanocomposites were characterized for
the particle size, size distribution and zeta potential using Zeta-
sizer (Malvern Instruments, UK).
2.6. Scanning electron microscopy (SEM) and Fourier
transform infrared spectroscopy (FT-IR) analysis
Morphological characteristics of the freshly prepared (CSA–
CDDP, CSA–CDDP–PEG, and CSA–CDDP–PEG–G)
nanocomposites were viewed using scanning electron micro-
scopy (SEM-Hitachi-S-2700), FT-IR spectrum was taken to
study the interaction between polymers and drug using Perkin
Elmer spectrum RXI. KBr pellets were concisely prepared by
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form Infrared spectroscopy (400–4000 cm1) was performed
with a resolution of 2 cm1.
2.7. TEM analysis
The shape and morphology of the Cisplatin loaded CSA,
CSA–PEG and CSA–PEG–G nanocomposites were investi-
gated by transmission electron microscopy (TEM, Hitachi
H-600-II) operated at 200 kV.
2.8. Determination of encapsulation efficiency (EE) and loading
capacity (LC)
The suspensions of the drug-loaded polymeric nanocomposites
were centrifuged at 17,000 rpm for 40 min and the EE and LC
of drug loaded polymeric nanocomposites were determined by
quantifying the absorption of the clear supernatant using a
UV-spectrophotometer (Elico SL 159, India). The correspond-
ing calibration curves were made by testing the supernatant of
blank polymeric nanocomposites. Tests were performed in
triplicate for each sample. The absorbance value of CDDP
was measured using a UV–vis spectrophotometer at the wave-
length of 290 nm. The percentage of encapsulation efficiency
and loading capacity of CDDP in the CSA, CSA–PEG and
CSA–PEG–G nanocomposites are determined by the follow-
ing equations (Eqs. (1) and (2)), respectively, as reported ear-
lier (Papadimitriou et al., 2008), which are as follows:
EE ¼ ðWt WfÞ=Wt  100% ð1Þ
LC ¼ ðWt WfÞ=Wn  100% ð2Þ
where Wt is the total amount of CDDP; Wf is the amount of
free CDDP in the supernatant after centrifugation; and Wn
is the weight of polymeric nanocomposites after freeze-
drying. All measurements were made in triplicate and the aver-
age value was reported.
2.9. Evaluation of in vitro drug release
The in vitro drug release tests were carried out on all formula-
tions (2%, 4%, 6%, 8%, and 10% drug loaded samples).
Nearly 0.1 mg of each sample was suspended in a definite vol-
ume (10 ml) of phosphate buffer saline (PBS) at various pH at
37 C. The resulting suspension was placed in an incubated
shaker at 120 rpm for a definite time period (1 h) and five-
milliliter aliquots were taken out of the dissolution medium
at appropriate time intervals (30 min), replaced by same vol-
ume of fresh PBS buffer, to keep the volume of the release
medium constant. The amount of drug released was observed
by UV spectrophotometer (Systronics, India) at 290 nm.
3. Results and discussion
3.1. Characterization of polymeric nanocomposites
3.1.1. Preparation and characterization of CDDP loaded
polymeric nanocomposites
Table 1 represents the particle size and zeta potentials of the
CDDP loaded polymeric nanocomposites. The size of thenanocomposites increases slightly with an increase in the %
of CDDP encapsulation. The size of the nanocomposites,
which is increased once again, is due to the coordination of
PEG and G with CSA–CDDP. The 10% of CDDP loaded
CSA, CSA–PEG, CSA–PEG–G nanocomposites displayed a
mean particle size value of 143,239 and 311 nm respectively
as shown in (Table 1).
Zeta potential tells about the charge on the surface of the
polymeric nanocomposites and plays an important role in the
stability of the particles in suspension through the electrostatic
repulsion between the particles (Wilson et al., 2011). The repul-
sion among the polymeric nanocomposites with the same type of
surface charge provides extra stability (Zhao et al., 2010). The
10% of CDDP loaded CSA, CSA–PEG, CSA–PEG–G
nanocomposites exhibited a mean zeta potential value of
24.6 mV,15.3 mV and10.0 mV, respectively (Table 1) that
lies in the stable range indicating that the prepared nanocom-
posite systems were stable. The negative values obtained for
the zeta potential indicate that the polymeric nanocomposites
surface is negatively charged. This negative charge may be due
to the availability of the free acetyl groups on the polymer.
Negative zeta potential values are detected in all cases, suggest-
ing that CSA chains are primarily located on the surface of the
particles. All the zeta potential experiments were done in the
aqueous medium after centrifuging the nanocomposites at
15,000 rpm for 30 min and dispersed in millipore water.
3.1.2. Fourier transmission infrared spectroscopy (FT-IR)
analysis
The FT-IR spectra of native and acetylated cassava starch are
given in Fig. 1. In the spectrum of native starch, there are some
discernible absorbencies at 1157, 1016 cm1, which are attribu-
ted to C–O bond stretching (Goheen and Wool, 1991). Other
characteristic absorption bands at 928, 859, 765, and
576 cm1 are due to the whole anhydroglucose ring stretching
vibrations (Cherif Ibrahima Khalil et al., 2011). The very broad
band between 3000–3600 cm1 and 2931 cm1 corresponds to
OH and CH stretching respectively (Kacurakova and Wilson,
2001) while the peaks at 1648 cm1 and 1420 cm1 correspond
to d (OH) and d (CH) bendings (Mano et al., 2003). Compared
to native starch, starch acetates had a strong absorption band
at 1730 cm1 that is attributed to the stretching vibration of
the ester carbonyl C‚O and indicated the acetylation of starch.
FT-IR spectra of various CSA–CDDP, CS–CDDP–PEG,
and CSA–CDDP–PEG–G nanopolymer composites are
shown in Fig. 2a. The CSA spectra exhibited band at
1730 cm1 relative to the stretching of the ester carbonyl
(C‚O) group of acetylated cassava starch. The addition of
PEG and gelatin led to bands at 1666 cm1 relative to the
stretching of the ester carbonyl group (Lin et al., 2007). Thus
the shift in the peak toward a lower field than the actual field
indicates the physical mixture of CSA, PEG, and gelatin. The
amino peak of gelatin in the polymer composite was shifted
from 1542 to 1547 cm–1. The amide I absorption was primarily
due to the stretching vibration of the C–O bond and the amide
II band was due to the coupling of the bending of the N–H
bond and the stretching of the C–N bond. This result proves
that there is an interaction between the CSA and the amino
groups of gelatin.
Furthermore, strong characteristic peaks of CDDP are not
sensed at the same position in the drug-loaded nanocompos-
Table 1 The particle size and zeta potential values of CSA–CDDP, CSA–CDDP–PEG and CSA–CDDP–PEG–G.
% of CDDP concentration Particle size (nm) mean ± SDa ZP (mV) mean SDa
CSA–CDDP CSA–CDDP–PEG CSA–CDDP–PEG–G CSA–CDDP CSA–CDDP–PEG CSA–CDDP–PEG–G
10 143.2 ± 12.5 239.0 ± 11.8 311.7 ± 05.0 24.6 ± 1.1 15.3 ± 1.4 10.0 ± 2.0
20 154.4 ± 12.7 245.5 ± 05.8 325.4 ± 10.1 22.3 ± 1.5 13.5 ± 1.7 08.1 ± 1.1
30 168.0 ± 08.6 261.3 ± 15.3 333.6 ± 12.4 20.1 ± 2.2 13.0 ± 1.5 07.3 ± 3.2
40 185.5 ± 11.3 270.1 ± 10.1 345.3 ± 10.3 18.8 ± 1.5 11.2 ± 2.3 06.1 ± 1.4
50 193.2 ± 12.5 274.8 ± 13.6 350.1 ± 07.2 19.5 ± 1.8 10.4 ± 1.4 05.5 ± 1.5
CDDP: Cisplatin; CSA: Cassava starch acetate; PEG: polyethylene glycol; G: gelatin; SD: standard deviation for three determinations.
a n= 3. The experiments were repeated twice.
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Figure 1 FTIR spectra of (a) acetylation of cassava starch, (b)
native cassava starch.
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Figure 2 FTIR spectra of (a) and (b) cisplatin loaded
nanocomposites.
Drug release of cisplatin loaded cassava starch acetate 13ites, identifying an interaction between the drug and the poly-
mer composites. Also, the peaks were shifted toward a lower
field than the actual field, and this shift was due to the hydro-
gen bond in the encapsulated polymer composites. Fig. 2b
indicates the FT-IR spectra of the 10 and 50% of CDDP
coated CSA–CDDP–PEG–G polymeric nanoparticles. The
spectra of the coated polymeric nanoparticles displayed the
same peaks that vary only in intensity.
3.1.3. Scanning electron microscopy (SEM) of drug loaded
polymeric nanocomposites
The SEM images of CSA–CDDP, CSA–CDDP–PEG and C
SA–CDDP–PEG–G nanocomposites are shown in Fig. 3.
In addition, the combination of CDDP with nanocompos-
ites produced a smooth surface and compact structure
Fig. 3b and c. Particle accumulation and a smooth surfacecan be seen in the SEM of the secondary mixed-film due to
the physical mixture of PEG and G to the CSA. The mixture
of CSA with CDDP exhibited certain immiscibility. A clear
uniform surface of the G cross-linked polymer composite is
shown in Fig. 3c. The coating lying of CDDP with CSA
exposed a rough surface. The coating lying of PEG with gela-
Figure 3 SEM images of cisplatin loaded (a) CSA, (b) CSA–PEG, (c) CSA–PEG–G nanocomposites.
Figure 4 TEM images of cisplatin loaded (a) CSA, (b) CSA–PEG, (c) CSA–PEG–G nanocomposites.
Table 2 Encapsulation efficiency (EE) and loading capacity (LC) of CSA–CDDP, CSA–CDDP–PEG and CSA–CDDP–PEG–G
nanocomposites.
% of CDDP concentration CSA–CDDP nanocomposites CSA–CDDP–PEG nanocomposites CSA–CDDP–PEG–G nanocomposites
% of EE % of LC % of EE % of LC % of EE % of LC
10 23.9 05.3 45.3 10.1 66.9 14.9
20 62.3 22.7 75.5 27.4 84.0 30.5
30 75.4 34.8 85.5 39.4 90.4 41.7
40 82.0 43.8 89.4 47.7 93.6 49.2
50 85.9 50.6 91.6 53.9 94.1 57.0
14 V. Raj, G. Prabhatin revealed a smoother surface and rod shaped structure, dis-
playing an enhanced encapsulation efficiency and a more con-
sistent structure.
3.1.4. Transmission electron microscopy (TEM) analysis
The surface morphology of the Cisplatin loaded CSA, CS–
PEG, and CSA–PEG–G nanocomposites was observed by
TEM as shown in Fig. 4. Fig. 4a–c illustrates that the CSA–
CDDP, CSA–CDDP–PEG, CSA–CDDP–PEG–G nanocom-
posites have spherical morphology and are homogeneously
distributed with an average diameter of 50–100 nm.
3.2. Encapsulation efficiency (EE) and loading capacity (LC)
The initial concentration of CDDP played a significant role in
deciding the drug encapsulation efficiency (EE) and drug load-
ing capacity (LC) of the CSA, CSA–PEG and CSA–PEG–G
nanocomposites as shown in Table 2. When the concentration
of CDDP is increased, the EE & LC of CSA, CSA–PEG and
CSA–PEG–G nanocomposites is also increased. The EE &
LC of CSA–PEG–G nanocomposites is somewhat more than
that of the CSA and CSA–PEG nanocomposites when at theinitial concentration of CDDP is same, which might be accred-
ited to the fact that CSA–PEG–G nanocomposites have more
attraction than CSA and CSA–PEG nanocomposites with
CDDP. The drug encapsulation efficiency (EE) and drug load-
ing capacity (LC) of high percentage of (50%) CDDP loaded
CSA, CSA–PEG & CSA–PEG–G nanocomposites were found
to be 85.9%, 91.6% & 94.1% and 50.6%, 53.9%, &57.0%,
respectively (Table 2).
3.3. In vitro drug release studies
In vitro drug release studies were done via direct dispersion
method as explained in the literature (Bisht et al., 2007;
Anitha et al., 2011) at pH 3.4 & 7.4 and release pattern is
shown in Fig. 5. The percentage release of CDDP from CSA
was slightly greater when compared to that of CSA–PEG
and CSA–PEG–G combined nanocomposites. For the CSA–
CDDP, CSA–CDDP–PEG and CSA–CDDP–PEG–G coated
nanocomposites, the percentage of CDDP released from the
nanocomposites was initially much larger and then very slow
after some hours, similar to that reported by other authors
(Li et al., 2008; Chen et al., 2009, 2011; Yang et al., 2008;
Figure 5 In vitro analysis of cisplatin encapsulated nanocomposites.
Drug release of cisplatin loaded cassava starch acetate 15Zhang et al., 2009). Fig. 5 shows the release profile at both the
pH for the same drug loading, as the pH value of the releasing
buffer increased, the releasing rate of CDDP increased. From
Fig. 5, we also found that the release rate of the CDDP which
was loaded in the CSA, CSA–PEG and CSA–PEG–G loaded
nanocomposites was much lower than the free CDDP. The
results indicated that the release of CDDP from CSA, CSA–
PEG and CSA–PEG–G nanocomposites is pH dependant,
the CDDP released faster in acidic environment than at basic
environment as a consequence of binding between drug and
the carboxyl group in cassava starch acetate nanocomposites
which could be recovered by the attacking of H+ or Cl. At
body environment, the Cl concentration is very high (95–
105 mM) and relatively stable in body circulation, more acidic
environment means more H+ which can speed up the release
of CDDP from the coated polymeric nanocomposites.
4. Conclusions
In this study, a novel formulation of CDDP loaded CSA,
CSA–PEG, CSA–PEG–G nanocomposites was successfully
developed and characterized. Size and shape of the prepared
nanocomposites were examined using SEM and TEM. Also,
the various suspended groups present in the composites have
been determined through the FT-IR studies. The nanocompos-
ites showed pH and time dependent drug release as confirmed
by the in vitro drug dissolution profiles. Drug penetration and
in vitro tests suggest that further study is required to develop
an in vivo drug delivery system. These results suggest that
the CDDP coated CSA, CSA–PEG and CSA–PEG–G
nanocomposites might be used as great potential carriers for
controlled drug delivery system.
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